51274-83-0

Basic information

• Product Name: N-(2-chloro-4-methyl-3-thienyl)-4,5-dihydro-1H-imidazol-2-amine monohydrochloride
• Synonyms: N-(2-chloro-4-methyl-3-thienyl)-4,5-dihydro-1H-imidazol-2-amine monohydrochloride;Thiamendine;Thiamenidine·hydrochloric acid
• CAS NO: 51274-83-0
• Molecular Formula: C8H11Cl2N3S
• Molecular Weight: 252.16404
• EINECS: 257-100-4
• Mol File: 51274-83-0.mol
• Article Data: 1

Chemical Properties

• Melting Point: 228-229°
• Boiling Point: 305.1°Cat760mmHg
• Flash Point: 138.3°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.00084mmHg at 25°C
• CAS DataBase Reference: N-(2-chloro-4-methyl-3-thienyl)-4,5-dihydro-1H-imidazol-2-amine monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloro-4-methyl-3-thienyl)-4,5-dihydro-1H-imidazol-2-amine monohydrochloride(51274-83-0)
• EPA Substance Registry System: N-(2-chloro-4-methyl-3-thienyl)-4,5-dihydro-1H-imidazol-2-amine monohydrochloride(51274-83-0)

Safety Data

• Hazardous Substances Data: 51274-83-0(Hazardous Substances Data)

Usage

Description

Tiamenidine hydrochloride is a centrally-acting antihypertensive structurally related to clonidine. In patients with mild to moderate hypertension, tiamenidine exerts similar activity to clonidine, but with fewer sympathomimetic side-effects.

Uses

Symcor(Hoechst-Roussel).

Brand name

Sundralen

InChI:InChI=1/C8H10ClN3S.ClH/c1-5-4-13-7(9)6(5)12-8-10-2-3-11-8;/h4H,2-3H2,1H3,(H2,10,11,12);1H

Relevant articles and documents

Method for treating central nervous system disorders with substituted 2-imidazoline derivatives

The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, X, A, and n are as defined in the specification and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms thereof.